A novel hydrophobic chitosan derivative, octanoyl chitosan (OC) with improved organic solubility was synthesized, characterized, and employed for the preparation of rifampicin (Rif) encapsulated nanoparticle formulations for pulmonary delivery. OC was characterized to confirm acyl group substitution and cytotoxicity in A549 epithelial lung cells. OC nanoparticles were produced by the double emulsion solvent evaporation technique without cross-linking and characterized for particle size distribution, morphology, crystallinity, thermal stability, aerosol delivery, and drug release rate. OC was successfully synthesized with substitution degree of 44.05 ± 1.75%, and solubility in a range of organic solvents. Preliminary cytotoxicity studies of OC showed no effect on cell viability over a period of 24 h on A549 cell lines. OC nanoparticles were optimized using a 3 2 full factorial design. An optimized batch of OC nanoparticles, smooth and spherical in morphology, had mean hydrodynamic diameter of 253 ± 19.06 nm (PDI 0.323 ± 0.059) and entrapment efficiency of 64.86 ± 7.73% for rifampicin. Pulmonary deposition studies in a two-stage impinger following aerosolization of nanoparticles from a jet nebulizer gave a fine particle fraction of 43.27 ± 4.24%. In vitro release studies indicated sustained release (73.14 ± 3.17%) of rifampicin from OC nanoparticles over 72 h, with particles demonstrating physical stability over 2 months. In summary, the results confirmed the suitability of the developed systems for pulmonary delivery of drugs with excellent aerosolization properties and sustained-release characteristics.
INTRODUCTION
Being the second leading cause of death worldwide from infectious diseases, after the human immunodeficiency virus (HIV) (1), tuberculosis (TB) is continuously posing a major global health problem. The latest estimate by the World Health Organization (WHO) indicated 10.4 million new cases of TB in 2016, of which 6.8 and 1.5 million cases, corresponding to 65 and 15%, were among men and women respectively, while 1.0 million (10%) were among children. People having co-infection of HIV with TB were calculated to be 1.2 million (10%) of all new TB cases, while drug-resistant TB is a continued threat (1) . Currently, chemotherapy is the only available option for the treatment of TB. However, it has several limitations such as lengthy treatment (requiring combination antibiotics therapy daily for 6-9 months), patient non-compliance, non-localized delivery, worsening of the disease due to co-infection with HIV and generation of drug-resistant mutants of TB bacilli. Moreover, high dose, dosing frequency, and adverse side effects are other major factors limiting the effectiveness of the current TB chemotherapy (2) . Among several anti-TB drugs, rifampicin (RIF) is one of the most effective and is an important component of DOTS (directly observed treatment, short-course) therapy. It is considered a model anti-TB drug, with well-defined chemical and physical properties. However, a series of limitations such as low bioavailability, enhanced drug resistance, less cell permeability, inability to achieve adequate drug concentrations at the infected site, and degradation before reaching the target site have impeded its effectiveness Electronic supplementary material The online version of this article (https://doi.org/10.1208/s12249-018-0972-9) contains supplementary material, which is available to authorized users. (2) . Therefore, developing an alternative delivery system and route of administration for rifampicin would clearly be advantageous.
The inhaled route of administration is receiving increasing attention for direct and target specific delivery of drug to the lungs due to the large alveolar surface area, extensive vascularization, limited proteolytic activity, avoidance of firstpass metabolism, and rapid onset of drug action (3) . However, lack of retention of drugs in the lungs and some invasive procedures for drug administration have hindered its clinical application (2) . Sustained and targeted drug delivery to the pulmonary site is usually achieved by formulating drugs in micro-or nanoparticle structures, which can be administered as a therapeutic aerosol. Formulation of anti-TB drug into nanoparticulate carrier system for pulmonary delivery could help to solve these issues associated with their current use. The small-sized colloidal nanoparticles have easy penetration into the alveoli, may have enhanced alveolar macrophage uptake compared to microparticles and can achieve an effective therapeutic outcome (4, 5) .
Several polymers have been employed for the preparation of nanoparticles for pulmonary delivery including, polylactic-coglycolic acid, polycaprolactone, chitosan, and alginates. (6, 7) Chitosan, a natural polymer, consisting mainly of β (1 → 4)-linked D-glucosamine and N-acetyl β-D-glucosamine, has been widely used owing to its advantages such as biodegradability, biocompatibility, mucoadhesive property (due to positive charge in aqueous environments), low toxicity, and antimicrobial activity (8) . Moreover, improved entrapment and uptake by the alveolar macrophages for effective targeting has made this polymer a choice for the lung delivery (4) . There are reports demonstrating application of chitosan microparticles and nanoparticles for delivery of drugs and macromolecules to the lung (9) (10) (11) (12) . However, loss of their positive surface charge, aggregate formation at physiologic pH, and their inability to protect and control the release of small molecular drugs have contributed to chitosan's current limited applications in drug delivery (13, 14) . Various chemical modifications of chitosan have been investigated in order to overcome these limitations by conjugating hydrophobic and hydrophilic groups (owing to the presence of reactive amine and hydroxyl groups) for application in drug/protein delivery (12, 15) . Modification of chitosan by acylation (using acyl chlorides and anhydrides) confers organic solubility and an ester linkage is hydrolyzable by enzymes such as lipase (13) . Several methods for synthesizing hydrophobic chitosan derivatives for biomedical applications have been reported (12, (16) (17) (18) , while nanoparticles were produced mainly by cross-linking, drying, reverse micellar, or emulsion crosslinking. The cross-linking method often involves the use of potential toxic agents such as glutaraldehyde, making this methodology less effective and tedious due to post-formulation removal of cross-linking agents. To the best of our knowledge, there have been no reports exploring hydrophobic chitosan derivative (OC) for the preparation of nanoparticles by emulsification without cross-linking.
Thus, the present study describes the utilization of hydrophobic chitosan in the preparation of nanoparticles for pulmonary delivery of rifampicin using an emulsion solvent evaporation technique without cross-linking. The aim of the study was to produce suitably sized rifampicin-loaded octanoyl chitosan nanoparticles using a freeze-drying process, while optimization of the formula was achieved by factorial design. MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) assay indicated the suitability of the presented polymer for safe use in drug delivery. The physicochemical properties, loading capacity (LC), encapsulation efficiency (EE), and release properties of encapsulated rifampicin were investigated, while stability studies indicated the stability of the octanoyl chitosan nanoparticles. In sum, this study clearly demonstrated positively charged nanoparticles with a release-controlling ability of octanoyl chitosan, suggesting its suitability as a novel drug carrier for pulmonary delivery.
MATERIALS AND METHODS

Materials
Rifampicin was purchased from Sigma-Aldrich (St. Louis, USA). Chitosan oligosaccharide [MW > 5 kDa; degree of deacetylation (DDA) 80-90%] was supplied by Kitto Life Co. Ltd. (Kyongki-Do, Seoul, South Korea). Octanoyl chloride, methane sulfonic acid, sodium bicarbonate, Poloxamer F-127, and polyvinyl alcohol (PVA) were purchased from Sigma-Aldrich (St. Louis, USA). Cellulose dialysis tubing (Molecular weight cut-off 12-14,000 Da and 5000 Da) was purchased from Medicell International Ltd., (London, UK). Dimethyl sulfoxide (DMSO, anhydrous), methanol, ethanol, chloroform, dichloromethane (DCM), acetone and all other HPLC grade solvents were obtained from Sigma-Aldrich (St. Louis, USA).
Methods
Preparation of OC and OC-Rif Nanoparticles
Octanoyl chitosan was synthesized as per the method described by Huang et al. with modifications and confirmed using NMR and FTIR studies (14) . The final product was further utilized to prepare nanoparticles (see supporting information).
OC nanoparticles were prepared using the double emulsion solvent evaporation technique as previously described (19) . Accurately weighed (50 mg) OC was dissolved in 1.5 ml of dichloromethane. The required quantity of rifampicin (5-15 mg) was dissolved in this solution with agitation until complete dissolution. Organic phase was emulsified immediately with aqueous phase by sonication for 15 s at 15 Amp to form a primary emulsion. The emulsion obtained was then poured into 10 ml of aqueous phase containing 0.5% PVA (polyvinyl alcohol) and sonicated at 15 Amp for 30 s (Labsonic® P, Sartorius Biotech GmbH, Germany). The resultant multiple emulsion was magnetically stirred (RO 10 power IKA WERKE, Staufen, Germany) at 25-30°C for about 4 h to completely evaporate the organic phase. Recovery of nanoparticles formed was achieved by centrifugation at 21000 rpm for 30 min (Sigma Laboratory Centrifuge, 3K30, UK). Samples were washed three times with fresh deionized water to remove any residual surfactant (PVA) and free drug. Nanoparticles obtained were then lyophilized (VirTis Co. Inc., UK) following addition of cryoprotectant, trehalose dehydrate (1% w/v) as described by Holzer et al., (20) . A similar protocol was followed to prepare blank OC NPs without rifampicin.
Optimization of Particle Size and Entrapment Efficiency by Factorial Design
Preliminary optimization was carried out to study the influence of process parameters such as sonication time, organic solvent, surfactant, and concentration of surfactant. Thereafter, blank OC NPs and rifampicin-loaded OC NPs (OC-Rif NPs) were prepared using a 3 2 randomized full factorial design. Accordingly, 9 possible combinations of experimental trials were prepared with three replicates. The concentration of polymer (X 1 ) and concentration of Rif (X 2 ) were selected as independent variables, while parameters mean particle size, MPS (Y1), and entrapment efficiency, EE (Y2), were selected as dependent variables (response parameters). The responses were analyzed by statistical modeling of interactive and polynomial terms. The response surface curves and contour plots were prepared to study the effects of independent variables. All the statistical operations were carried out using Design-Expert software, version 8.0.7.1 (Stat-Ease Inc., Minneapolis, USA), Statistica (StatSoft, Tulsa, USA) and Microsoft Excel 2010 (I) (Gurgaon, India). Independent factors at their varied combinations in terms of coded and their actual values are represented in Table I .
Optimization and Data Analysis. The optimization of parameters was carried out by applying response surface methodology (RSM) computations using Design Expert® software (version 8.0.5.2, Stat-Ease Inc., Minneapolis, MN), Statistica (Stat soft, Tulsa, USA), and Microsoft Excel 2010. Multiple regression analysis (MLRA) was used to generate polynomial models (including interaction and quadratic terms) for the response variable and its Eq. (1) can be presented as below.
where b 0 is the intercept corresponding to the arithmetic average of quantitative outcomes of 9 runs, b 1 to b 7 signifies coefficients calculated from the experimentally observed values of Y, and X 1 and X 2 stands for the coded levels of the independent variables. The terms X 1 X 2 represent interaction term, while X i (2) (I = 1 to 2) denotes quadratic terms. The main effects, X 1 and X 2, symbolizes the mean outcome because of changing one factor at a time from its low to high value, while the interaction terms (X 1 X 2 ) indicate changes in the response parameters when two factors are simultaneously changed. Non-linearity in the model was also investigated by the polynomial terms (X 1 2 and X 2 2 ). The polynomial equation as mentioned above was utilized to interpret the results based on the values of magnitude of coefficients and the accompanying positive (synergistic effect) or negative sign (antagonistic effect) (21) .
Statistical validity of the polynomials was determined using ANOVA as provided in the Design-Expert ®software (Stat-Ease, USA) and Microsoft Excel 2010 (I) at a significance level of p < 0.05. In addition, 3D response surface curves, and the 2D contour plots were also developed by the Statistica® software (Stat Soft, Tulsa, USA). The best fitting mathematical model was chosen by comparing various statistical parameters such as the coefficient of variation (CV), the multiple correlation coefficient (R 2 ), adjusted multiple correlation coefficient (Adj R 2 ), and the predicted residual sum of squares (PRESS). For the chosen model, smaller the PRESS value in relation to the other models under consideration signifies how well the model fits the data (19) .
Characterization of OC-Rif Nanoparticles
Mean Particle Size and Zeta Potential. Dynamic light scattering (DLS) and laser Doppler velocimetry (LDV) was employed to measure particle size (expressed as mean hydrodynamic diameter and polydispersity index; PDI) and surface charge (zeta potential) of the particles respectively using Zetasizer, Nanoseries Instrument (Nano 25, Malvern Instruments, Worcestershire, UK). The nanoparticles were re-dispersed in deionized water and bath sonicated (Ultrawave Ltd., UK) for 5 min and the resultant samples were examined for particle size and zeta potential.
R i f a m p i c i n L o a d i n g a n d E n c a p s u l a t i o n Efficiency. Encapsulation of rifampicin in NPs was evaluated by dissolving OC-Rif NPs in methanol and analyzed using UV-VIS spectrophotometer. A known weight of Rif loaded nanoparticles was suspended in methanol, allowed to stand for around 10-15 min and water was added in a sufficient amount to precipitate OC. The suspension obtained was centrifuged (Bio Rad Centrifuge, UK) and the concentration of rifampicin in the supernatant was determined using UV-VIS spectrophotometer (Jenway UV/Vis Spectrophotometer, Staffordshire, UK) at 475 nm (22) (Benetton et al., 1998) . Analysis was performed in triplicate for each batch of drug loaded NPs. The yield, drug loading and encapsulation efficiency were calculated using following formulae and presented as mean of each of the parameter: Morphology Determination by Scanning Electron Microscopy. Lyophilized nanoparticles were observed using scanning electron microscopy (SEM) to study their shape and surface morphology. The samples were mounted onto the SEM sample holder and gold coated in a vacuum chamber and images were recorded at the required magnification at the acceleration voltage of 10 kV using FEI XL30 TMP Scanning electron microscope (FEI XL30 TMP, Philips, Netherlands).
Transmission Electron Microscopy. Nanoparticles were also visualized by transmission electron microscopy (TEM). Briefly, a drop of nanoparticle suspension was stained with phosphotungstic acid and placed on a coated carbon grid and vacuum dried. The grid was then examined immediately under TEM (Philips Electron Optics BV, Netherlands) and the electron micrographs were obtained.
Differential Scanning Calorimetry and X-ray Powder Diffraction Studies. A differential scanning calorimeter (DSC Q 2000, TA Instruments, USA) was used to determine the thermal properties of the freeze-dried nanoparticles (OCRif-NPs) and rifampicin. Correctly weighed samples (around 3-5 mg) of the stated materials were placed in hermetically sealed aluminum pans; a sealed empty aluminum pan was used as a reference. Heating runs for each sample were set from 10°C to 300°C at 10°C min −1 in a nitrogen atmosphere to get the heating scan (thermographs). X-ray powder diffractometry was carried out using an X-ray diffractometer (Oxford Diffraction Xcalibur novaT, UK) and diffractograms obtained were analyzed to understand physical state of the powder. The samples were mounted on a sample holder and X-ray powder diffraction (XRD) patterns were recorded in the range of 5-50°at the speed of 5°per min.
Aerosolization and Aerosol Characterization Using TwinStage Impinger
The aerosolization of OC-Rif nanoparticle formulations was determined following nebulization using a TSI (Glass Impinger, Apparatus A Ph. Eur; Copley Scientific Ltd., Nottingham, UK) as per the specifications given in the European Pharmacopoeia (23) . In brief, lyophilized OC-Rif NP samples (10 mg) were prepared by dispersing in 5 ml deionized water. The required volume (5 ml) was loaded into a PariBoy air-jet nebulizer with Inhaler Boy compressor (Pari Medical, UK). The aerosol generated was directed into the TSI via a mouthpiece adaptor, and a vacuum pump set at a flow rate of 60 L/min was used to draw the aerosol through the impinger. The upper and lower stages (stage 1 and stage 2) of the TSI were filled with 7 and 30 ml of deionized water respectively. The nebulization was performed until aerosol generation stopped (nebulizer dryness). Thereafter, the nebulizer was gently tapped to achieve maximum output. Samples from stages 1 and 2 of TSI were rinsed with small known quantities of methanol and made up to 20 and 25 ml respectively with deionized water. The amount of rifampicin deposited in each stage and that remaining in the nebulizer was determined using UV-VIS spectrophotometer (Jenway UV/Vis Spectrophotometer, Staffordshire, UK). The aerodynamic behavior of the nanoparticle suspension was evaluated by calculating nebulization efficiency (NE) and fine particle fraction (FPF) using Eqs. 5 and 6 (8, 24) . The effective size cut-off between stages for the TSI is 6.4 μm; thus, drug deposited in stage 2 is the fine particle dose (FPD) and the proportion of aerosol generated aerosol deposited in stage 2 is considered the FPF, representing that proportion of delivered product in nebulized droplets having aerodynamic diameter less than 6.4 μm, and predicted to be likely to deposit in the lower airways. Experiments were performed in triplicate and mean values of each parameter are reported.
Nebulization efficiency ¼ aerosolized drug mass drug mass loaded in nebulizer x 100 
In vitro Release Studies
Rifampicin-loaded OC nanoparticles were tested for their ability to release rifampicin from the OC-Rif NPs. In vitro release study was carried out in the dark with a 
OC octanoyl chitosan dialysis method using modified release technique (25) . Simulated lung fluid (SLF-pH 7.4) with 200 μg/ml of ascorbic acid (to prevent oxidative degradation of rifampicin) was used as the dissolution medium. A known amount of OC-Rif NPs (10 mg) was dispersed in SLF and transferred to dialysis membrane of which one end was previously sealed with dialysis tubing clamp. After complete transfer of the formulation, another end of the dialysis membrane was sealed and placed in a beaker containing 25 ml of SLF as external release media under stirring at 37°C. At selected time intervals, suitable aliquots were withdrawn from the external medium, diluted as required, and analyzed by HPLC (Agilent Technologies 1200 series) at 335 nm (26) . Sink condition was maintained (after withdrawal of aliquot at each time points) by replenishing the same amount of blank media. The experiment was carried out in triplicate and results of the release study were plotted as percent cumulative drug release vs time.
HPLC Analysis. The amount of rifampicin released from OC-Rif NPs was analyzed by HPLC (Agilent Technologies 1200 series) equipped with a UV detector to quantify the amount of rifampicin release. The injection volume was 10 μl. Chromatography was performed with a column (Ascentis C18, 150 × 4.6 mm, 5 μm, Supelco, Sigma-Aldrich, USA). Mobile phase comprised tetrahydrofuran (THF)/phosphate buffer (30/70%) at a flow rate of 1.0 ml/min and a detection wavelength of 335 nm (26) . The column temperature was set to 40°C. The retention time of rifampicin was 3.5 min. A calibration curve of pure rifampicin was prepared at concentrations ranging from 5 to 80 μg/ml and was used for quantification of rifampicin in samples.
Cytotoxicity of Octanoyl Chitosan Derivative on A549 Cells Determined by MTT Assay
The MTT cell proliferation assay for OC was performed using the MTT dye reduction assay according to the method described by Kroll et al. (27) . The cytotoxicity profiles of OC were studied in the adenocarcinomic human alveolar basal epithelial cell line (A549) over the period of 48 h. The cells (passage no. [45] [46] [47] [48] [49] were cultured in 96-well plates with 100 μl complete medium [RPMI-1640, supplemented with fetal bovine serum (10%, FBS) and antimycotic antibiotic solution (1%)] and incubated at 37°C (5% CO 2 incubator) for the period of 24 h. Samples (100 μl) were prepared in complete medium and added to the wells in a concentrations ranging from 0 to 5 mg/ml and incubated for a further 48 h. After incubation, 40 μg/ml MTT solution (5 mg/ml in PBS, pH 7.4) was added to each well and the plates were again incubated for 2 h at 37°C (5% CO 2 incubator). Medium was carefully replaced with 100 μl of DMSO in each well to solubilize formazan crystals and the absorbance was read at 570 nm using an ELISA plate reader (SpectraMAX 190, Molecular Devices). The results from the MTT experiments were graphed as percentage of cell growth in comparison to the control wells containing only the cells in the medium and dimethyl sulfoxide (DMSO, 10%) as a positive control. The relative cell viability (%) was calculated using the following equation:
Cell viability % ð Þ ¼ OD of test well OD of reference well x 100 ð7Þ
Stability Study
Lyophilized OC-Rif NPs were stored in desiccator for 2 months at ambient room temperature (20-25°C) to determine their stability. After 2 months storage, samples (2 mg) were taken to determine particle size and percentage of rifampicin in the formulation (OC-Rif NPs).
Statistical Analysis
Experiments were performed in triplicate and the data collected are expressed as the mean value ± standard deviation. Results of the factorial design were statistically analyzed using ANOVA (Microsoft Excel Corp, India) and Statistica (Stat soft Inc., Tulsa, USA) by generating various polynomial equations.
RESULTS AND DISCUSSION
Preparation of Nanoparticles and Characterization
Chitosan nanoparticles have previously been prepared using many methods such as ionic gelation, complex coacervation, emulsion cross-linking, and spray drying (28) . In addition, polymeric micelles (amphiphilic, self-assembly) prepared using modified chitosan derivatives have also been explored for drug delivery (12, (29) (30) (31) . However, there are no reports of the preparation of nanoparticles directly from hydrophobic chitosan derivatives (OC) using the double emulsion solvent evaporation (DESE) technique without cross-linking. Hence, the current investigation assessed the feasibility of using OC in the preparation of nanoparticles (NPs) and examined the incorporation of rifampicin into OC NPs as a system for the potential treatment of TB via pulmonary route. The DESE method was successfully utilized for the preparation of NPs from OC. Initially, blank OC NPs were prepared and preliminary experiments helped to select optimal parameters such as sonication time, solvent, surfactant, and concentration of surfactant (results are given in supporting information). Once the preliminary parameters were chosen, rifampicin-loaded OC NPs were prepared and optimized employing a 3 2 factorial design.
Optimization of Formulation by Factorial Design
Based on the preliminary formulation optimization studies, various process parameters required for preparation of OC NPs were selected, which helped to avoid the complexity of experimental design. Thus, optimized parameters such as organic phase (DCM-3.5 ml); internal aqueous phase (0.5 ml); external aqueous phase (10 ml, 0.5% PVA); sonication pulse (15 W); and sonication times of 15 and 30 s for primary and secondary emulsion respectively were kept constant in factorial design studies. Influence of parameters such as concentrations of OC (X 1 ) and rifampicin (X 2 ) were optimized by applying a 3 2 factorial design of experiment consisting of nine formulation batches with random variation of rifampicin and OC at three levels. Table II shows the combination of independent variables and observed responses in terms of mean particle size, entrapment efficiency, and other parameters (PDi, zeta potential, yield and drug loading, etc.) for all the nine formulations.
Effect of Formulation Variables on the Response Parameters
, and 10 respectively) using multiple regression analysis and Fstatistic to determine statistically significant terms.
Multiple regressions analysis revealed no significant influence of factors X 1 , X 2 , and X 22 on the response parameter MPS, while factors X 2 and X 22 were found to be statistically significant (p < 0.05) for % EE. The multiple regression analysis suggested quadratic models as shown in Eqs. 11 and 12 for both MPS and EE respectively. The observed and predicted values of MPS and EE for all the batches of OC-Rif NPs are tabulated in Table III Regression output and full model responses for dependent variables, namely MPS and EE of formulation OC-Rif NPs are displayed in Table IV . The MPS and EE observed after random combinations of three levels of two independent variables (X1 and X2) were subjected to multiple regression analysis which revealed statistical significance (p < 0. It was observed that, the MPS values ranged from 208.17 ± 26.81 nm to 323.57 ± 65.80 nm and entrapment efficiency (EE) of Rif in OC NPs was between 25.4 ± 3.77% and 64.86 ± 7.73%. A considerably higher entrapment of rifampicin (64.86 ± 7.73%) was achieved at low levels (− 1) of X1 (50 mg) and high level of X2 (15 mg) from batch C3. Equations 10 and 11 display the quantitative effect of formulation components (independent variables X1 and X2) on response parameters (Y1 and Y2), in the form of corresponding polynomial equations and regression coefficients for mean particle size (MPS-Y1) and mean % entrapment efficiency (EE-Y2).
Each coefficient in equations 10 and 11 was evaluated and the significance determined on the basis of the p values, as shown in Table IV . The smaller the p value (p < 0.05), the more statistically significant is the corresponding coefficient. The data obtained from the full model of MPS confirms that the main effects of the independent variables (X 1 , X 2 , and X 22 ) were statistically significant for prediction of MPS as their p values were well below 0.05 (p < 0.05), while the interaction term X 1 X 2 had little predictive effect as their p values were above 0.05 (p > 0.05) and hence were excluded from the model. From the results of EE, p values below 0.05 (p < 0.05) were noted for the independent variables X 2, X 22 suggesting their statistical significance. Remaining factors such as X 1, X 11 and the interaction term X 1 X 2 had p values (p > 0.05), and therefore they were considered less important in the given model.
The coefficients of the two independent variables in quadratic Eq. 10 were compared and the coefficient value for X 1 (b1 = 24.89) was found to be maximum suggesting it was the major contributing factor which affects the mean particle size of OC-Rif NPs. On the other hand, quadratic Eq. 11 showed maximum coefficient values for independent variable X 2 (b1 = 12.76), and hence it was the major factor affecting EE. In both cases, positive values of X 1 and X 2 are an indication of synergistic effect of OC and rifampicin concentration on MPS and EE. Significance of quadratic model terms X 1 and X 2 in Eq. 10 (MPS), and significance of quadratic terms X 2 and X 22 in Eq. 11 (EE) suggested nonlinearity (non-significant) in the ability of independent variables (X 1 and X 2 ) to influence MPS and EE respectively. The combined effect of factors X 1 and X 2 can be further elucidated with the help of contour plots and response surface curves as shown in Figs. 1a, b and 2a, b .
The predicted residual sum of squares (PRESS) is also known as sum of squared residuals (SSR) or the sum of squared errors of prediction (SSE). PRESS values indicate how well the model fits the data, and it is recommended that, for the chosen model the value of PRESS should be relatively small as compared to the other models under consideration (32) . The polynomial model which shows lower PRESS value determines the fitness of data, and hence such model is selected. In the given experiment, PRESS value was calculated for the full and reduced polynomial model for both the independent variables (Y1 and Y2). Results indicated the suitability of the full polynomial model as compared to the reduced model, with smaller PRESS values for both Y1 (223.96) and Y2 (24.73), whereas the reduced model showed higher PRESS values for Y1 (1493.53) and Y2 (109.17).
Figures 1a, b and 2a, b show contour plots and 3D response surface plots for both response parameters; MPS and EE respectively, depicting the effects of independent variables X 1 and X 2 on dependent variables Y1 and Y2. No significant difference in the MPS and EE was noted, when the value of X 1 was varied from low (− 1) to high (+ 1) level, keeping X 2 constant at low level (− 1). In the similar set up of experiment, when the value of X 2 was increased from low level (− 1) to medium level (0), a non-significant decrease in the particle size was noted which also led to corresponding nonsignificant decrease in the % EE. Further increase in the concentration of X 2 significantly increased EE, while a nonsignificant increase of MPS was observed. Comparing MPS, it was observed that small MPS values in the range of 208.17 ± 26.81 to 323.57 ± 65.80 nm were obtained from all the batches (C1 to C9), with smallest MPS obtained at medium level of X 1 and X 2 from batch C5 . The same batch demonstrated the smallest EE (25.4 ± 3.77%). In a different combination, where values of X 2 were increased from low (− 1) to high (+ 1) level and X 1 kept constant at low level n = 3; mean ± Standard Deviation OC-octanoyl chitosan; Rif-rifampicin; MPS-mean particle size; PDI-polydispersity index; EE-entrapment efficiency; DL-drug loading; ZP-zeta potential. Table V .
Effect of Polymer Concentration and Theoretical Drug Loading on MPS, EE, and ZP
A non-significant influence of theoretical drug loading (DL) on MPS was observed at all levels. Theoretical DL of 5, 10, and 15 mg of rifampicin resulted in MPS of 242.8 ± 44.36, 214.4 ± 26.58, and 253.43 ± 19.06 nm respectively. Similar results were obtained even when the concentration of polymer was increased from 50 to 75 and 100 mg. Such a relation between the theoretical DL and polymer concentration on MPS was also observed by Doan et al. (33) . Although MPS from all the batches were obtained in the range of 208.17 ± 26.81 to 323.57 ± 65.80 nm, larger MPS was observed when the concentration of polymer and drug was increased. Formulation C1-C3 consisting of lowest concentration of OC (50 mg) and varying amounts of Rif (5-15 mg) showed lowest values of PDI (0.292 ± 0.036 to 0.323 ± 0.059), whereas increasing concentration of OC to 75 and 100 mg led to increase in the PDI values suggesting broader particle distributions (PDI > 0.4). Non-significant increases in the MPS (276.8 ± 58.58 nm and 323.57 ± 65.80 with PDI of 0.427 ± 0.107 and 0.413 ± 0.188) with increased amount of OC (75 and 100 mg) may be due to an increase in the viscosity of the organic phase in the emulsion, which might have caused hindrance in the efficiency of sonication. Reports have also suggested possible collision and merger of nanoparticles leading to large MPS, when higher polymer concentration was used for the preparation of NPs (34, 35) . Based on the results of this study, batch C3 composed of 50 mg of polymer and 15 mg of Rif exhibited optimum particle size with uniform size distribution as compared to other batches prepared with other combinations of OC-Rif concentration.
Factorial design of experiment yielded formulation batches with the variable entrapment efficiencies of Rif in OC. At low polymer concentration (50 mg), the highest entrapment efficiency (64.86 ± 7.73%) was obtained, when the theoretical DL was kept at a higher level of 15 mg (batch C3). Similar pattern of results in terms of increased EE was observed when the amount of OC was increased to 75 and 100 mg in batch C6 and C9 with the corresponding EE of 58.33 ± 7.27 and 56.72 ± 2.037% respectively. The use of the highest OC concentration (100 mg) for the preparation of NPs led to non-significant decrease in the EE, which may be due to enhanced viscosity of the system contributing to hampered sonication and stirring (36) . Considerably lower EEs of 36.83 ± 9.35% and 28.77 ± 0.44% were noted at lower theoretical DL of 5 and 10 mg respectively. The same trend was noted in all the batches studied. Thus, a non-significant change in the entrapment efficiency was observed at low and medium theoretical drug loading at all polymer concentrations, while high theoretical drug loading showed increased entrapment efficiency, which may be due to higher amount of drug available for entrapment. ( 37,38) Similar results have been reported previously (39, 40) . Other studies have also reported increased theoretical DL associated with increased EE and size (41, 42) . PDI relates to the distribution of particle sizes in a sample of particles. Smaller PDI values close to 0 are preferred, indicating a narrow size distribution (43) . Results of this study demonstrated acceptable PDI values at low polymer concentration, while higher PDI values (> 0.4) were observed for the batches prepared using higher amounts of OC (Table II) . A positive zeta potential conferred by the polymers is usually preferred in the delivery of small molecules and macromolecules due to advantages such as ease in surface assimilation of negatively charged materials such pDNA and RNA, drugs, and even proteins, and their ability to interact with cells thereby providing high transfection efficiency (44) . Moreover, cationic polymers have also been explored for the purification of water (45) . The current investigation was directed to modify chitosan while retaining its positive charge. All the batches from C1 to C9 showed positive ZP ranging from + 18.83 ± 8.44 to + 35.90 ± 2.07 mV. Although no correlation between charge on the particles and amount of drug was seen, increasing the polymer concentration had a positive influence on the charge. This enhancement in the ZP can be rated as C1 < C4 < C7 (+ 18.83 ± 8.44 < + 28.8 ± 3.13 < + 35.90 ± 2.07 mV) and C2 < C5 < C8 and C3 < C6 < C9, with respect to increase in polymer concentration. Increased ZP values for rifampicin-loaded OC NPs, as compared to their blank counterparts were observed. This increased ZP could be attributed to the particle-associated rifampicin (adsorbed), which might have influenced surface charge owing to the presence of amino groups in the rifampicin molecule (46) .
Optimization of Responses Using Desirability Function (47)
The difficulty of multiple and sometimes opposing responses is usually overcome by an optimization technique involving desirability function. Each response is affiliated with its own partial desirability function. The value of 1 for the desirability function is always preferred as it is considered optimal, while value of zero means the result is treated unacceptable. The desirability for each response can be calculated at a given response point in the experimental design. When the goal is to minimize the given response, the following formula can be used to calculate individual desirability.
where d 1 is individual desirability, Y i (mps) is experimental results of response MPS. Ui and Ti stand for maximum and target MPS respectively. Similarly, if one wants to maximize the stated response, Eq. 15 can be used to calculate individual desirability. 
where, k denotes total number of responses. Optimum parameters for the formulation were generated utilizing a numerical optimization technique by the desirability function approach. Response parameters such as Y1 and Y2 were optimized and the optimized formula was finalized by keeping the mean particle diameter in the range 200 to 300 nm and EE between 50 and 70%. Batch C3 (containing low (− 1) level of variable X 1 and high level of variable X 2 ) resulted in the optimum formula. Individual desirability for MPS and EE was calculated and found to be 1, indicating acceptability of the model for the optimization of formula. Similarly, overall desirability for the current model was also found to be 1, indicating suitability of the model for optimization purposes. Moreover, the result of the experimental and predicted values for MPS and EE confirmed the practicability and validity of the model. Relative errors for both MPS and EE were found to be below 10% indicating that the response surface methodology (RSM) optimization technique was appropriate for optimization for the preparation of NPs from the novel polymer and for incorporation of Rif in OC NPs.
Optimized Formulation
The rigorous optimization process yielded a final formula (Table VI) , which was used in further studies. Table VI also shows the predicted and observed values of various parameters.
Lyophilization of OC-Rif NPs was done in the presence of trehalose as a cryoprotective agent at a concentration of 1% (20) . Almost comparable results with respect to mean particle size were achieved in the samples before (231.9 ± 20.37) and after lyophilization (253.43 ± 19.06 nm), with no significant change in mean size following lyophilization (P > 0.05). This has indicated the suitability of trehalose (1%) as a cryoprotectant during lyophilization.
Particle Characterization
Particle Size and Surface Charge OC-Rif NPs prepared using the optimized final formula were centrifuged and washed to remove any unentrapped materials (Rif and PVA) and mean hydrodynamic diameter, PDI, and zeta potential were determined prior to freeze drying (FD). The preparation had mean particle size of 231.9 ± 20.37 nm, PDI of 0.384 ± 0.022, and ZP of + 28.2 ± 1.67 mV. After redispersion of freeze-dried OC-Rif-NP powder, the measured values for MPS, PDI, and ZP were very similar (Table VI) .
Morphology of OC-Rif NPs After Freeze Drying
The size, shape, and surface morphology of nanoparticles were visualized by scanning and transmission electron microscopy (SEM and TEM) (Fig. 3a, b) respectively. OC-Rif NPs were uniform in size and morphology, showed small particle diameter, spherical shape, and smooth surface morphology.
Solid-State Characterization of OC-Rif NPs
Differential Scanning Calorimeter
Thermal analysis of rifampicin, OC, OC-Rif physical mixture and OC-Rif NPs formulation was performed using DSC and the data obtained in the form of thermograms are presented in Fig. 4 . Thermograms revealed a characteristic exothermic peak at 260°C for rifampicin with no endothermic and exothermic peak between 20 to 300°C in the thermogram of OC. However, an exothermic peak was observed above 300°C in the thermogram of chitosan, which is attributed to monomer dehydration, glycoside bond cleavage and decomposition of the acetyl and deacetylated units of chitosan. Similar results have been reported previously (48, 49) . Similarly, physical mixture of OC and rifampicin did not show any endothermic or exothermic peak for OC, but an exothermic peak corresponding to rifampicin was observed at 260°C. Owing to the absence of endothermic or exothermic peak in OC thermograms, DSC thermographs of OC-Rif NPs formulation were also devoid of endothermic or exothermic peaks. In addition, the absence of a peak for rifampicin in the OCRif NPs suggested molecular dispersion of rifampicin in OC NPs. 
X-ray Powder Diffraction
X-ray diffractograms of rifampicin, chitosan, OC, and OC-Rif NPs are shown in Fig. 5 . Characteristic crystalline peaks at 2θ values of 13°and 15°for rifampicin were observed in the powder XRD diffractograms. XRD of Rif indicated the crystalline nature of rifampicin. Parent chitosan (chitosan > 5 K) showed a characteristic broad peak of moderately low intensity at around 20°, whereas a sharp peak at 20°and a new peak of higher intensity below 2 theta value of 8 were observed in the XRD spectra of OC. XRD studies revealed a broad diffuse peak for rifampicin-loaded NPs (OC-Rif NPs). The absence of crystalline peak of rifampicin in the OC-Rif NPs suggested the presence of rifampicin in amorphous form in OC NPs and its molecular dispersion in OC NPs. Presence of a broad diffuse peak in XRD diffractograms of rifampicin-loaded OC NPs is a general characteristic for such systems composed of binary components (50) . Results from XRD have demonstrated that crystallinity of rifampicin was altered by its encapsulation into OC nanoparticle formulation.
Aerosol Characterization Using the Twin-Stage Impinger
Samples for TSI studies were prepared by dispersing 10 mg of OC-Rif NPs in 5 ml deionized water and nebulized using a PariBoy air-jet nebulizer into the TSI (Table VII) .
Following nebulization to dryness 0.45 ± 0.06 mg of RIF was deposited in stage 2 of the TSI (i.e. the FPD) representing an FPF of 43.27 ± 4.24%. The amount of drug remaining in the nebulizer, caused by the residual volume (51) of the nebulizer was found to be 0.59 ± 0.06 mg giving a nebulizer efficiency of 77.04 ± 4.33%.
These findings indicate the suitability of the jet nebulizer to deliver rifampicin, in a mucoadhesive NP carrier system to the lower respiratory tract. Such nebulizers have previously been reported to achieve efficient aerosolization of nanocarriers (6, 52) , with the small particles being efficiently delivered in the relatively large nebulized aerosol droplets which are efficiently delivered to the lower stage of the TSI and human lower respiratory tract.
In vitro Drug Release
The cumulative percentage release of Rif from Rifampicin suspension (Rif-S) and OC-Rif NPs was investigated in vitro over a period of 2 h and 72 h respectively. Experiment was performed in triplicate and release curves plotted as cumulative percentage drug release vs time are shown in Fig. 6 . Simulated lung fluid (SLF 4, pH 7.4) was used as a release medium, to mimic the biological environment within Results showed immediate release of almost all the rifampicin (87.65 ± 10.29%) from Rif-S into release medium, whereas release of rifampicin was retarded from the OC NPs. OC-Rif NPs displayed initial rifampicin release of 5.23 ± 3.15%, indicating the ability of the polymer matrix to control the release of drug. OC-Rif NPs exhibited sustained and steady release over the period of study (72 h), with a biphasic drug release pattern. Initially, a sustained-release phase was observed until 6 h, which was followed by a steady, slower drug release. In the initial phase (up to 6 h), 45.97 ± 2.99% of rifampicin release was noted, which may have been due to dissolution and passive diffusion of Rif located on or near the surface of nanoparticles. In addition, penetration of aqueous release medium (SLF pH 7.4) into the hydrophobic polymeric matrix leading to slow dissolution and thereby diffusion of the drug from the OC NP matrix may also have caused sustained initial release up to 6 h. After 6 h, a slower release of drug occurred, leading to loss of 73.14 ± 3.17% of drug at 72 h. The second phase of drug release is probably due to the diminution of rifampicin in the polymeric matrix, leading to a reduced concentration gradient, causing less drug to be released. Hence, the biphasic release pattern of the formulation can be ascribed to the localization of rifampicin onto and within the immediate layer and core of the prepared nanoparticles. These results agree with the observations described by Klariae et al. (53) .
The release profiles obtained were fitted using various mathematical models, namely: zero-order, first-order, Higuchi, Hixon-Crowell, and Korsemeyers-Peppas models to explore the kinetics of drug release from OC nanoparticles (54) . The results of different model fittings are given in Fig. 6 . Among various models tested, the curve fitting of release data to the Korsemeyers-Peppas model gave a higher value of correlation coefficient (r 2 value of 0.8243) with the Bn^value (0.911, which is 0.5 < n < 1), suggesting an anomalous transport (non-fickian) mechanism for rifampicin release. Thus, the Korsemeyers-Peppas model satisfactorily represented the data owing to diffusion of rifampicin from the OC NPs.
Cytotoxicity Studies of OC
A very important criterion determining the suitability of polymers in drug delivery is their cytotoxicity. Non-cytotoxic materials are always preferred while choosing carrier materials for drug delivery. Cationic agents are reported usually to confer cytotoxicity owing to their interaction with negatively charged cellular elements or proteins (55) . However, chitosan and its derivatives are described as less cytotoxic than other cationic polymers (for instance poly-lysine and polyethyleneimine) (56) . The cytotoxicity caused by chitosan and its derivative is mainly determined by the factors such as type of chitosan derivative and type of cells under study (54) . This study used chitosan derivatives and tested the viability of cells treated with OC by application of the MTT assay (Fig. 7) . Results indicated nonsignificant changes in the cell viability at the examined concentrations of OC in comparison to the controls (positive and negative), demonstrating in vitro biocompatibility of OC over the concentration range studied. n = 3, mean ± SD NE-nebulization efficiency; FPF-fine particle fraction; FPD-fine particle dose
Stability Studies
OC-Rif NPs were assessed for their ability to maintain their mean particle size and size distribution along with their content of rifampicin over the period of 2 months storage at ambient temperature (Table VIII) . No significant differences (P > 0.05) were observed for drug content, mean particle size or PDI values of OC-Rif NPs, confirming the stability of OC-Rif NPs at ambient room temperature (20-25°C) . Hence, no special storage conditions were necessary up to 2 months.
CONCLUSIONS
This study has shown that derivatization of chitosan with a hydrophobic octanoyl chain increased the hydrophobicity of the polymer with no cytotoxicity. Octanoyl chitosan was successfully utilized to prepare nanoparticle preparations using double emulsion method, which is frequently used for preparation of nanoparticles. However, chitosan, nanoparticles often have to be hardened by cross-linking with potentially toxic agents. Formulations were optimized by factorial design. The optimized batch, with optimum physico- chemical parameters exhibited good incorporation of rifampicin in the octanoyl chitosan nanoparticles. Electron microscopy revealed spherical particles with smooth surfaces, while DSC and XRD studies indicated molecular dispersion of rifampicin in the octanoyl chitosan nanoparticles. The sphericity and positive surface charge of the octanoyl chitosan nanocarriers are expected to increase cell surface affinity and uptake of nanocarriers (57) . In addition, the mucoadhesive/ bioadhesive property of chitosan would potentially increase the residence time of the formulations in the lungs, successfully delivered from a jet nebulizer, which might enhance the efficiency of antibiotic for the treatment of infections. Biodegradability and non-cytotoxicity (as determined by MTT assay) of this natural polymer suggests its likely safety in clinical use. In sum, the results of this study have demonstrated the desirable potential of octanoyl chitosan and octanoyl chitosan nanoparticles for lung delivery of rifampicin. Further evaluations in animals are required to further evaluate its utility and potential clinical use. 
